Liquid biopsies in metastatic renal cell carcinoma (mRCC) provide a unique approach to understand the molecular basis of treatment response and resistance. This is particularly important in the context of immunotherapies, which target key immune-tumor interactions. In this study from HIP Investigator Dr. Meggang Yu, researchers collected 457 longitudinal liquid biopsies from 104 patients with mRCC enrolled in one of two studies, either a prospective cohort or a phase II multicenter adaptive immunotherapy trial.
Using a novel CTC capture and automated microscopy platform, they profiled CTC enumeration and expression of HLA I and programmed cell death-ligand 1 (PD-L1). They identified the prognostic importance of CTC enumeration and the change over time of both CTC enumeration and the HP ratio.
Read More